View in EDS PDF Full Text

Topical intra articular tranexamic acid reduces packed blood cell consumption in total joint arthroplasty.

Saved in:
Bibliographic Details
Title: Topical intra articular tranexamic acid reduces packed blood cell consumption in total joint arthroplasty.
Alternate Title: El ácido tranexámico intraarticular tópico reduce el consumo de glóbulos rojos concentrados en la artroplastía articular total.
Authors: Fraind-Maya, G.1 fraind29@gmail.com, Nasrawy, T.1, Kandel, L.1, Greenberg, A.1, Liebergall, M.1, Perets, I.1, Laniado-Nahmad, D.1, Rivkin, G.1
Source: Acta Ortopédica Mexicana. Jan/Feb2026, Vol. 40 Issue 1, p35-39. 5p.
Subjects: TRANEXAMIC acid, ARTHROPLASTY, BLOOD transfusion, BLOOD loss estimation, TOTAL knee replacement, TOPICAL drug administration, THROMBOEMBOLISM, HEMOGLOBINS
Abstract (English): Introduction: post-operative blood loss anemia is an undesired event following total joint arthroplasty. Use of tranexamic acid (TXA) has been shown to reduce blood loss after surgery and can be administered intravenously, orally and topically. We assessed the effect of topical intra articular TXA administration at the end of surgery in total joint arthroplasty on post-operative packed blood cell units’ consumption. Objective: assess the effect of topical intra-articular TXA administration in reduction of packed blood cell units’ consumption postoperatively. Material and methods: this is a retrospective study comparing two groups of patients that had either a primary total knee arthroplasty (TKA) or primary total hip arthroplasty (THA) during a four months’ period before and after the beginning of intra articular administration of a solution containing 2 grams of TXA. Pre-operative hemoglobin level, post-operative day one hemoglobin level, packed blood cell administration and venous thromboembolism events (VTE) were assessed. Results: a total of 282 patients were reviewed, 148 records of patients that had a TKA and 134 records of patients that had THA. There were 80 and 68 TKA without and with TXA administration, respectively. There were 84 and 50 THA without and with TXA administration, respectively. There was no difference between the groups with regard to preoperative anticoagulation and aspirin treatment and VTE risk assessment. There was also no difference regarding preoperative hemoglobin levels. Patients undergoing THA and TKA showed a significant decrease in the hemoglobin level between preoperative levels to hemoglobin on postoperative day. However, administration of TXA ameliorated this decrease in hemoglobin levels, from 2.77 to 2.18 g/dl in hip arthroplasty (p < 0.001) and from 2.92 to 1.72 g/dl in knee arthroplasty (p < 0.001). In the THA group 13 packed blood cell units were administered without TXA compared to two units in patients treated with TXA (p < 0.001). In the TKA group 15 packed blood cell units were administered without TXA compared to two units in patients treated with TXA (p < 0.001). There were no VTE events in the THA patients. In the TKA patients, pulmonary embolism was diagnosed in two patients not treated with TXA and in three patients that were treated with intra articular TXA (p = 0.66). Conclusion: intra-articular topical administration of TXA at the end of surgery significantly reduced need for post-operative packed blood cell units’ administration without increases in VTE risk in all patients undergoing primary THA and TKA. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Introducción: la anemia por pérdida de sangre postoperatoria es un evento no deseado tras una artroplastía articular total. Se ha demostrado que el uso de ácido tranexámico (TXA) reduce la pérdida de sangre tras la cirugía y puede administrarse por vía intravenosa, oral y tópica. Evaluamos el efecto de la administración tópica intraarticular de TXA al final de la cirugía en la artroplastía articular total sobre el consumo de las unidades de células sanguíneas empaquetadas postoperatorias. Objetivo: evaluar el efecto de la administración tópica intraarticular de TXA en la reducción del consumo de unidades de células sanguíneas empaquetadas tras la operación. Material y métodos: este es un estudio retrospectivo que compara dos grupos de pacientes que se sometieron a una artroplastía primaria total de rodilla (ATR) o una artroplastía primaria total de cadera (ATC) durante un período de cuatro meses antes y después del inicio de la administración intraarticular de una solución que contenía 2 gramos de TXA. Se evaluaron los niveles preoperatorios de hemoglobina, el nivel de hemoglobina del primer día postoperatorio, la administración de células sanguíneas empaquetadas y los eventos de tromboembolismo venoso (TEV). Resultados: se revisaron un total de 282 pacientes, 148 registros de pacientes con una ATR y 134 registros de pacientes con ATC. Había 80 y 68 ATR sin y con administración de TXA, respectivamente. Había 84 y 50 ATC sin y con administración de la TXA, respectivamente. No hubo diferencias entre los grupos en cuanto al tratamiento reoperatorio de anticoagulación y aspirina ni en la evaluación de riesgos de TEV. Tampoco hubo diferencia en los niveles de hemoglobina preoperatorios. Los pacientes sometidos a ATC y ATR mostraron una disminución significativa del nivel de hemoglobina entre los niveles preoperatorios y la hemoglobina en el día postoperatorio. Sin embargo, la administración de TXA mitigó esta disminución de los niveles de hemoglobina, pasando del 2.77 al 2.18 g/dl en la artroplastía de cadera (p < 0.001) y del 2.92 al 1.72 g/dl en la artroplastía de rodilla (p < 0.001). En el grupo de ATC se administraron 13 unidades de células sanguíneas empaquetadas sin TAX en comparación con dos unidades en pacientes tratados con TXA (p < 0.001). En el grupo ATR se administraron 15 unidades de células sanguíneas empaquetadas sin TXA, en comparación con dos unidades en pacientes tratados con TXA (p < 0.001). No hubo eventos de TEV en los pacientes con ATC. En los pacientes con ATR, se diagnosticó embolia pulmonar en dos pacientes no tratados con TXA y en tres pacientes tratados con TXA intraarticular (p = 0.66). Conclusión: la administración intraarticular tópica de TXA al final de la cirugía redujo significativamente la necesidad de administración de unidades de células sanguíneas empaquetadas postoperatorias sin aumentar el riesgo de TEV en todos los pacientes sometidos a ATC primaria y ATR. [ABSTRACT FROM AUTHOR]
Copyright of Acta Ortopédica Mexicana is the property of Sociedad Mexicana de Ortopedia, AC and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 191464683
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Topical intra articular tranexamic acid reduces packed blood cell consumption in total joint arthroplasty.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: El &#225;cido tranex&#225;mico intraarticular t&#243;pico reduce el consumo de gl&#243;bulos rojos concentrados en la artroplast&#237;a articular total.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Fraind-Maya%2C+G%2E%22&quot;&gt;Fraind-Maya, G.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;&lt;i&gt; fraind29@gmail.com&lt;/i&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Nasrawy%2C+T%2E%22&quot;&gt;Nasrawy, T.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kandel%2C+L%2E%22&quot;&gt;Kandel, L.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Greenberg%2C+A%2E%22&quot;&gt;Greenberg, A.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Liebergall%2C+M%2E%22&quot;&gt;Liebergall, M.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Perets%2C+I%2E%22&quot;&gt;Perets, I.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Laniado-Nahmad%2C+D%2E%22&quot;&gt;Laniado-Nahmad, D.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Rivkin%2C+G%2E%22&quot;&gt;Rivkin, G.&lt;/searchLink&gt;&lt;relatesTo&gt;1&lt;/relatesTo&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Acta+Ortop&#233;dica+Mexicana%22&quot;&gt;Acta Ortop&#233;dica Mexicana&lt;/searchLink&gt;. Jan/Feb2026, Vol. 40 Issue 1, p35-39. 5p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22TRANEXAMIC+acid%22&quot;&gt;TRANEXAMIC acid&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22ARTHROPLASTY%22&quot;&gt;ARTHROPLASTY&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22BLOOD+transfusion%22&quot;&gt;BLOOD transfusion&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22BLOOD+loss+estimation%22&quot;&gt;BLOOD loss estimation&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22TOTAL+knee+replacement%22&quot;&gt;TOTAL knee replacement&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22TOPICAL+drug+administration%22&quot;&gt;TOPICAL drug administration&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22THROMBOEMBOLISM%22&quot;&gt;THROMBOEMBOLISM&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22HEMOGLOBINS%22&quot;&gt;HEMOGLOBINS&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Introduction: post-operative blood loss anemia is an undesired event following total joint arthroplasty. Use of tranexamic acid (TXA) has been shown to reduce blood loss after surgery and can be administered intravenously, orally and topically. We assessed the effect of topical intra articular TXA administration at the end of surgery in total joint arthroplasty on post-operative packed blood cell units’ consumption. Objective: assess the effect of topical intra-articular TXA administration in reduction of packed blood cell units’ consumption postoperatively. Material and methods: this is a retrospective study comparing two groups of patients that had either a primary total knee arthroplasty (TKA) or primary total hip arthroplasty (THA) during a four months’ period before and after the beginning of intra articular administration of a solution containing 2 grams of TXA. Pre-operative hemoglobin level, post-operative day one hemoglobin level, packed blood cell administration and venous thromboembolism events (VTE) were assessed. Results: a total of 282 patients were reviewed, 148 records of patients that had a TKA and 134 records of patients that had THA. There were 80 and 68 TKA without and with TXA administration, respectively. There were 84 and 50 THA without and with TXA administration, respectively. There was no difference between the groups with regard to preoperative anticoagulation and aspirin treatment and VTE risk assessment. There was also no difference regarding preoperative hemoglobin levels. Patients undergoing THA and TKA showed a significant decrease in the hemoglobin level between preoperative levels to hemoglobin on postoperative day. However, administration of TXA ameliorated this decrease in hemoglobin levels, from 2.77 to 2.18 g/dl in hip arthroplasty (p &lt; 0.001) and from 2.92 to 1.72 g/dl in knee arthroplasty (p &lt; 0.001). In the THA group 13 packed blood cell units were administered without TXA compared to two units in patients treated with TXA (p &lt; 0.001). In the TKA group 15 packed blood cell units were administered without TXA compared to two units in patients treated with TXA (p &lt; 0.001). There were no VTE events in the THA patients. In the TKA patients, pulmonary embolism was diagnosed in two patients not treated with TXA and in three patients that were treated with intra articular TXA (p = 0.66). Conclusion: intra-articular topical administration of TXA at the end of surgery significantly reduced need for post-operative packed blood cell units’ administration without increases in VTE risk in all patients undergoing primary THA and TKA. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Introducci&#243;n: la anemia por p&#233;rdida de sangre postoperatoria es un evento no deseado tras una artroplast&#237;a articular total. Se ha demostrado que el uso de &#225;cido tranex&#225;mico (TXA) reduce la p&#233;rdida de sangre tras la cirug&#237;a y puede administrarse por v&#237;a intravenosa, oral y t&#243;pica. Evaluamos el efecto de la administraci&#243;n t&#243;pica intraarticular de TXA al final de la cirug&#237;a en la artroplast&#237;a articular total sobre el consumo de las unidades de c&#233;lulas sangu&#237;neas empaquetadas postoperatorias. Objetivo: evaluar el efecto de la administraci&#243;n t&#243;pica intraarticular de TXA en la reducci&#243;n del consumo de unidades de c&#233;lulas sangu&#237;neas empaquetadas tras la operaci&#243;n. Material y m&#233;todos: este es un estudio retrospectivo que compara dos grupos de pacientes que se sometieron a una artroplast&#237;a primaria total de rodilla (ATR) o una artroplast&#237;a primaria total de cadera (ATC) durante un per&#237;odo de cuatro meses antes y despu&#233;s del inicio de la administraci&#243;n intraarticular de una soluci&#243;n que conten&#237;a 2 gramos de TXA. Se evaluaron los niveles preoperatorios de hemoglobina, el nivel de hemoglobina del primer d&#237;a postoperatorio, la administraci&#243;n de c&#233;lulas sangu&#237;neas empaquetadas y los eventos de tromboembolismo venoso (TEV). Resultados: se revisaron un total de 282 pacientes, 148 registros de pacientes con una ATR y 134 registros de pacientes con ATC. Hab&#237;a 80 y 68 ATR sin y con administraci&#243;n de TXA, respectivamente. Hab&#237;a 84 y 50 ATC sin y con administraci&#243;n de la TXA, respectivamente. No hubo diferencias entre los grupos en cuanto al tratamiento reoperatorio de anticoagulaci&#243;n y aspirina ni en la evaluaci&#243;n de riesgos de TEV. Tampoco hubo diferencia en los niveles de hemoglobina preoperatorios. Los pacientes sometidos a ATC y ATR mostraron una disminuci&#243;n significativa del nivel de hemoglobina entre los niveles preoperatorios y la hemoglobina en el d&#237;a postoperatorio. Sin embargo, la administraci&#243;n de TXA mitig&#243; esta disminuci&#243;n de los niveles de hemoglobina, pasando del 2.77 al 2.18 g/dl en la artroplast&#237;a de cadera (p &lt; 0.001) y del 2.92 al 1.72 g/dl en la artroplast&#237;a de rodilla (p &lt; 0.001). En el grupo de ATC se administraron 13 unidades de c&#233;lulas sangu&#237;neas empaquetadas sin TAX en comparaci&#243;n con dos unidades en pacientes tratados con TXA (p &lt; 0.001). En el grupo ATR se administraron 15 unidades de c&#233;lulas sangu&#237;neas empaquetadas sin TXA, en comparaci&#243;n con dos unidades en pacientes tratados con TXA (p &lt; 0.001). No hubo eventos de TEV en los pacientes con ATC. En los pacientes con ATR, se diagnostic&#243; embolia pulmonar en dos pacientes no tratados con TXA y en tres pacientes tratados con TXA intraarticular (p = 0.66). Conclusi&#243;n: la administraci&#243;n intraarticular t&#243;pica de TXA al final de la cirug&#237;a redujo significativamente la necesidad de administraci&#243;n de unidades de c&#233;lulas sangu&#237;neas empaquetadas postoperatorias sin aumentar el riesgo de TEV en todos los pacientes sometidos a ATC primaria y ATR. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Acta Ortop&#233;dica Mexicana is the property of Sociedad Mexicana de Ortopedia, AC and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=191464683
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.35366/122371
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 5
        StartPage: 35
    Subjects:
      – SubjectFull: TRANEXAMIC acid
        Type: general
      – SubjectFull: ARTHROPLASTY
        Type: general
      – SubjectFull: BLOOD transfusion
        Type: general
      – SubjectFull: BLOOD loss estimation
        Type: general
      – SubjectFull: TOTAL knee replacement
        Type: general
      – SubjectFull: TOPICAL drug administration
        Type: general
      – SubjectFull: THROMBOEMBOLISM
        Type: general
      – SubjectFull: HEMOGLOBINS
        Type: general
    Titles:
      – TitleFull: Topical intra articular tranexamic acid reduces packed blood cell consumption in total joint arthroplasty.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fraind-Maya, G.
      – PersonEntity:
          Name:
            NameFull: Nasrawy, T.
      – PersonEntity:
          Name:
            NameFull: Kandel, L.
      – PersonEntity:
          Name:
            NameFull: Greenberg, A.
      – PersonEntity:
          Name:
            NameFull: Liebergall, M.
      – PersonEntity:
          Name:
            NameFull: Perets, I.
      – PersonEntity:
          Name:
            NameFull: Laniado-Nahmad, D.
      – PersonEntity:
          Name:
            NameFull: Rivkin, G.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan/Feb2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 23064102
          Numbering:
            – Type: volume
              Value: 40
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Acta Ortopédica Mexicana
              Type: main
ResultId 1